ClinicalTrials.gg
CompletedNCT04263584COPA-R-CHOPUpdated Jul 30, 2026

Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

A Phase 2 interventional study of Copanlisib and R-CHOP Chemotherapy in Diffuse Large B Cell Lymphoma, sponsored by University Hospital Muenster. Completed at 16 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by University Hospital Muenster · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany — 15 open to participants now, 27 under way, 7 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Germany.

Enrollment
80th of 100
62 · median 156
Started
2020
with 3 others
Phase 2
30 of 108
4 open now
Registered
78th of 108
by date

Among the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany, this one is the 80th largest by enrollment of the 100 interventional ones that give a count, is one of 4 that started in 2020, is one of 30 in phase 2, and was the 78th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

15 of the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany, or all of them as a file.
02

Study summary

This is a prospective, multicenter, non-randomized, open-label, phase II study to describe the efficacy of R-CHOP plus copanlisib including a safety run-in phase in order to detect early and common unexpected toxicities caused by the addition of copanlisib to the standard immuno-chemotherapy R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL)

Read the detailed description

Patients diagnosed with DLBCL can be cured with a combined approach of CHOP chemotherapy and the anti-CD20 antibody rituximab in roughly 65% of cases. About one third of patients with DLBCL relapse or show primary progressive disease after modern first-line therapy. The outcome of these patients is poor in particular if first-line therapy contained rituximab. Novel therapeutic approaches are urgently warranted. Thus, it is the goal to further improve progression-free Survival (PFS) and overall Survival (OS) by combining R-CHOP with copanlisib. Copanlisib is a small molecule pan-class 1 PI3K inhibitor and approved by US FDA for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma

Keywords

  • Copanlisib
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed

    1. DLBCL (NOS) or
    2. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or
    3. High-grade B-cell lymphoma (NOS)
    4. Follicular lymphoma Grade 3B (primary diagnosis without history of indolent lymphoma) with a diagnostic performed within 3 months before study entry and with material available for central review and complimentary scientific analyses
  2. 18-80 years of age
  3. International Prognostic Index (IPI) 2-5
  4. Performance status (ECOG) 0-2
  5. of at least 3 months
  6. Women of and men must agree to use effective when sexually active. This applies for the time period between signing of the form and 6 months after the last administration of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%), e.g. intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner and sexual abstinence. The use of condoms by male patients is required unless the female partner is permanently sterile.

    Adequate baseline laboratory values collected no more than 7 days before starting study treatment:

  7. Total ≤ 1.5 x (\< 3 x ULN for patients with Gilbert syndrome, patients with cholestasis due to compressive adenopathies of the hepatic hilum or documented liver involvement or with biliary obstruction due to lymphoma)
  8. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement by lymphoma)
  9. Lipase ≤ 1.5 x ULN
  10. (GFR) ≥ 40 mL/min/1.73 m2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. If not on target, this evaluation may be repeated once after at least 24 hours either according to the CKD-EPI formula or by 24-hour sampling. If the later result is within acceptable range, it may be used to fulfill the inclusion criteria instead.
  11. and PTT ≤ 1.5 x ULN
  12. count ≥ 75,000 /mm3.
  13. (Hb) ≥ 8 g/dL
  14. (ANC) ≥ 1,500/mm3
  15. ≥ 50%
  16. No prior lymphoma therapy
  17. Ability to understand and willingness to sign written informed consent. Signed informed consent must be obtained before any study specific procedure.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria at the time of screening will be excluded.

  1. Previous assignment to treatment during this study. Patients permanently withdrawn from study participation will not be allowed to re-enter the study.
  2. Previous (within 28 days or less than 5 half-lives of the drug before start of study treatment) or concomitant participation in another clinical study with medicinal product(s).
  3. Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent persons (e.g. employee or student of the investigational site).

    Excluded medical conditions:

  4. Type I or II diabetes mellitus with > 8.5% at screening or fasting plasma glucose > 160 mg/dL at screening
  5. History or concurrent condition of interstitial lung disease and/or severely impaired lung function (as judged by the investigator)
  6. Known lymphoma involvement of the central nervous system
  7. (HIV) infection
  8. (HBV) and C () infection. Patients with serologic markers of HBV immunization due to vaccination (HBsAg negative, Anti-HBc negative and Anti-HBs positive) will be eligible
  9. CMV-PCR positive at baseline
  10. Previous or concurrent history of within 5 years prior to study treatment except for curatively treated:

    1. Cervical carcinoma in situ
    2. Non-melanoma skin cancer
    3. Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])
    4. Localized prostate cancer
  11. Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ Grade 3 within 4 weeks prior to the start of study medication
  12. Patients with seizure disorder requiring medication
  13. Proteinuria of ≥ CTCAE Grade 3 as assessed by a 24h protein quantification or estimated by urine protein: creatinine ratio > 3.5 on a random urine sample
  14. Concurrent diagnosis of pheochromocytoma
  15. Congestive heart failure > (NYHA) class 2
  16. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
  17. Myocardial infarction less than 6 months before start of test drug
  18. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication
  19. Non-healing wound, ulcer, or bone fracture
  20. Active, clinically serious infections > CTCAE Grade 2
  21. Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
  22. Known history of drug induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver or portal hypertension
  23. Ongoing inflammatory bowel disease
  24. History of, or current disease
  25. Prior treatment with PI3K inhibitors
  26. Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give
  27. Patient is pregnant (β-HCG positive) or breast-feeding
  28. Known to copanlisib or to any of the of rituximab, cyclophosphamide, doxorubicine, vincristine, and/or prednisone
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Copanlisib and R-CHOP chemotherapy

    All patients will receive 6 cycles of R-CHOP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/ m², vincristine 1.4 mg/m² (dose capped at 2 mg or 1 mg for individuals above 60 years of age), prednisolone 500 mg. In addition, copanlisib at a dose of 60 mg will be administered on days 1 and 8 of each 21-day cycle of R-CHOP in the first 6 patients. If dose limiting toxicity (DLT) occurs in no more than one out of these 6 patients during cycle 1, additional 6 patients at 60 mg will be enrolled and treated for at least 1 cycle before opening the phase II portion of the study. If a DLT is observed in 2 or more of the first 6 patients during cycle 1 the dose of copanlisib will be reduced to 45 mg on days 1 and 8 for the next 6 patients. The data of the safety run-in analysis (first 12 patients) will be presented to the Data Safety Monitoring Board and the recommended phase 2 dose will be determined.

    Drug: Copanlisib · Drug: R-CHOP Chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. 2-year progression-free survival

    Length of time that a patient lives without disease progression or relapse.

    Time frame: From the day of inclusion into the study until event (disease progression, relapse, death due to any other cause) occurs, assessed up to 4 years.

Secondary outcomes

  1. Overall survival

    The percentage of patients in this study who are still alive.

    Time frame: From the day of inclusion into the study to death due to any cause, assessed up to 4 years.

  2. Event-free survival

    Length of time that a patient remains free of certain events (disease progression, start of additional, unplanned antitumor therapy, relapse, death due to any other cause).

    Time frame: From the day of inclusion into the study until event (disease progression, start of additional, unplanned anti-tumor therapy, relapse, death due to any other cause) occurs, assessed up to 4 years.

  3. Rate of complete remission

    Rate of complete remission measured as number of complete remissions divided by the number of patients included.

    Time frame: From the day of inclusion into the study until date of complete remission, assessed up to 4 years.

  4. Rate of partial remission

    Rate of partial remission measured as number of partial remissions divided by the number of patients included.

    Time frame: From the day of inclusion into the study until date of partial remission, assessed up to 4 years.

  5. Overall response rate

    Overall response rate measured as number of complete and partial remissions divided by the number of patients included.

    Time frame: From the day of inclusion into the study until date of complete or partial remission, assessed up to 4 years.

  6. Progression rate

    Progression rate measured as number of progressions divided by the number of patients included.

    Time frame: From the day of inclusion into the study until date of progression during therapy or within 2 months after last treatment course.

  7. Relapse rate

    Relapse rate measured as number of relapses divided by the number of patients included.

    Time frame: From the day of inclusion into the study until date of relapse during therapy or within 2 months after last treatment course.

  8. Duration of response

    The time between the initial response to therapy and subsequent disease progression or relapse.

    Time frame: From documentation of tumor response to relapse, assessed up to 4 years.

  9. Adverse events and serious adverse events

    Frequency of adverse events and serious adverse events

    Time frame: The documentation of adverse events, including serious adverse events, starts with first study treatment after patient inclusion and ends 100 days after the last application of copanlisib or any component of R-CHOP

  10. Rate of treatment-related deaths

    The number of deaths during therapy or up to 2 months after the end of therapy divided by the number of patients included.

    Time frame: From the start of therapy up to 2 months after the end of therapy.

  11. Therapy cycles (number)

    Number of therapy cycles

    Time frame: From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years.

  12. Therapy cycles (duration)

    Duration of therapy cycles

    Time frame: From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years.

  13. Used drugs

    Cumulative doses of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) and copanlisib.

    Time frame: From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years.

  14. Outcome according to lymphoma biology

    Lymphoma tissue from all patients will be characterized.

    Time frame: From the start of study until the end of study, assessed up to 4 years.

07

Study locations

16 sites
  • University Hospital RWTH Aachen
    Aachen, 52074, Germany
  • Haematology and Oncology Practice
    Augsburg, 86150, Germany
  • Klinikum-Bremen-Mitte
    Bremen, 28205, Germany
  • St.-Johannes-Hospital Dortmund
    Dortmund, 44137, Germany
  • Onkozentrum Dresden
    Dresden, 01127, Germany
  • University Hospital Halle
    Halle, 06120, Germany
  • University Medical Center Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Westpfalz-Klinikum
    Kaiserslautern, 67655, Germany
  • Karlsruhe City Hospital
    Karlsruhe, 76133, Germany
  • ÜBAG MVZ Dr. Vehling-Kaiser GmbH
    Landshut, 84036, Germany
  • University Hospital Leipzig
    Leipzig, 04103, Germany
  • Ludwigshafen City Hospital
    Ludwigshafen, 67063, Germany
  • Hospital of the Ludwig-Maximilians-University (LMU) Munich
    Munich, 81377, Germany
  • University Hospital Muenster
    Münster, 48149, Germany
  • Hospital Stuttgart - Stuttgart Cancer Center
    Stuttgart, 70174, Germany
  • University Hospital Ulm
    Ulm, 89081, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2025, 58 months.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's 58 months is close to that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Feb 11, 2020
StartActual
Jun 19, 2020
Primary completionActual
May 3, 2025
CompletionActual
May 3, 2025
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04263584
Collaborators
Bayer
Responsible party
Sponsor
First posted
Feb 11, 2020
Start date
Jun 19, 2020
Primary completion
May 3, 2025
Completion
May 3, 2025
Last update
Jul 30, 2026

Study contacts

Prof. Georg Lenz, MD
principal investigator · University Hospital Muenster

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Copanlisib · R-CHOP protocol

Start the discussion